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Obesity is a widespread problem within modern society,serving to increase the risk of 
cardiovascular, metabolic, and neurodegenerative disorders. Peroxisome proliferator-activated 
receptor gamma (PPARγ) and PPARγ coactivator 1 α (PGC1α) play a key role in the regulation of 
cellular energy metabolism and may be implicated in the pathology of these diseases. This study 
examined the association between polymorphisms of the PPARG and PPARGC1A genes,PPARG 
gene expression, risk of obesity and efficiency of intervention including physical activity and 
hypocaloric diet on weight loss. 
Methods 
Thirty-nineobese Ukrainian women (44.4 ± 7.5 years, BMI > 30.0 kg/m2) undertook a 3-month 
fitness programwhilst following a hypocaloric diet (~1500 calories). Anthropometric (BMI, body 
fat percentage, and visceral fat) and biochemical (high- and low-density lipoproteins, cholesterol, 
triglyceride) measurements took place before and after the program. Single nucleotide 
polymorphisms within or near PPARG (n=94) and PPARGC1A(n=138) were identified and 
expression of PPARG mRNA was measured via reverse transcription and amplification. 
Theassociation betweenDNApolymorphisms and weight loss, initial body mass, biochemistry and 
PPARG expression was determined using one-way analysis of variance (ANOVA). 
Results 
The present intervention induced significant fat loss in all participants (total fat: 40.3±5.3 vs 
36.4±5.7%; P<0.00001). Only one polymorphism (rs17650401 C/T) within the PPARGC1A gene 
was found to be associated with fat loss efficiency after correction for multiple testing, with T allele 
carriers showing the greatest reduction in body fat percentage (2.5-fold; P=0.00013) compared to 
non-carriers.  
Conclusion 
PPARGC1A (rs17650401) is associated with fat loss efficiency in obese women. Further studies are 










Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptors demonstrated 
toplay a keyrole in carbohydrate and lipid metabolism,from the single cell to the whole organism. 
These receptors are classified into three families; PPAR, PPAR, and PPAR. PPAR controls 
lipid storage and synthesis1. Its activation leads to triacylglycerol production and accumulation in 
liver, differentiation and proliferation of adipocytes, increased synthesis of both adiponectin and 
resistin2, and regulation of the immune system response via areduction in inflammatory activity of 
lymphocytes3,4. Peroxisome proliferator-activated receptor-gamma coactivator (PPARGC1A)is a 
transcriptional coactivator that regulates the genes involved in energy production5. 
Additionally,PPARGC1Ais involved in NO-induced mitochondrial biogenesis, along with switching 
of muscle metabolism towards oxidative phosphorylation, thusadapting muscle tissueto endurance 
training6.A number of single nucleotide polymorphisms (SNPs) within the PPAR gene family are 
associated with a predisposition to metabolic, cardiovascular, and neurodegenerative disorders, such 
as obesity, dyslipidemia, hypertension, cancer,type 2 diabetes, and Parkinson’s disease7,8.  
Obesity is a major problem withinmodern society, withthe percentage of affected adults in 
comprising ofup to 40% of the population in many developed countries9. Obesity is associated with 
an increased prevalence of cardiovascular diseases, type 2 diabetes, gastrointestinal and oncological 
disorders10,11. Designinga personalizedweight loss strategy may be an effective tool in reducing the 
spread of mentioned diseases. 
To date, there is a limited data demonstrating the effects of SNPs within the genesof the 
PPAR family on weight loss through increased physical activity. PPARG polymorphismsare known 
to influence variability ofbody mass index (BMI) independently of sex, age, energy intake, and 
physical activity12.However,the effects of these polymorphismson exercise-induced weight loss 
have not been previously characterized. Thepurpose of this study, therefore, was to identify SNPs 
withinPPARG and PPARGC1A associated with total and visceral fat percentage, blood lipoprotein 
and triglyceride concentrations, as well as their modifyinginfluenceon the efficacy of moderate 
physical exercise in terms ofweight loss. 
 
Materials and methods 
Ethic statement 
This study was approved by the National Academy of Science of Ukraine Bogomoletz Institute of 
Physiology Biomedical Ethics Committee, Kyiv, Ukraine (#1/18 05.04.2018). Written informed 
consent was obtained from the participants,and the study conformed to the guidelines and principles 
of the Declaration of Helsinki. 
 
Participants 
The study participants were 39 Ukrainian middle-aged women (44.4±5.8 years of age),of which 
32%had no previous physical activity experience. Inclusion criteria included a BMI ofgreater than 
30, and an absence of biochemical signs of severe metabolic syndrome (i.e. normal LDL, HDL, 




All participants were enrolled into a 3-month fitness program, which included 180 minutes of 
aerobic exercise per week with an average metabolic equivalent (MET) value of 6. Depending on 
the baseline physical fitness levels of each participant,exercise heart ratedid not exceed 115–125 
bpm (low fitness), 125–135 bpm (moderate fitness), or 135–145 bpm (well-adapted).Heart rate was 
measured usingPolar RC3 GPS with Polar heart rate sensor H7 (Finland).Additionally, throughout 
the study period, the participants were advised to maintain a healthy hypocaloric diet (~1500 
calories), avoid high-sugar, high-fat, and processed food diets, and to include more vegetables and 
wholemeal products in their diet. 
 
Anthropometric and Blood Measurements 
All measurements were done before and after the exercise lifestyle intervention. BMI was 
calculated as body weight in kilograms divided by the square of the height in meters. Percentage of 
total and visceral fat was measured by bioelectrical impedance analysiswith “TANITA – BC-
418MA” body composition analyser (Japan). For the blood biochemical test, blood samples were 
collected from the antecubital vein after an overnight fast. Plasma glucose was measured by the 
standard method. HDL, LDL, and triglycerides were measured via direct methods.  
 
Genotyping  
The samples of 39 subjects were sent to the commercial laboratory (Akesogen, UK), where DNA 
was extracted from the saliva samples using Qiagen chemistry on an automated Kingfisher FLEX 
instrument (Thermo Fisher Scientific, Waltham, MA, US), following the manufacturer’s 
recommended protocols and standard operating procedures. PicoGreen and Nanodrop 
measurements were taken to measure the quality and quantity of the DNA. Input to the custom 
testing array occurs at 200 ng in 20 μl. Amplification, fragmentation, and resuspension was 
performed using Biomek FXP following Affymetrix’s high throughput protocol for Axiom 2.0. 
Hybridization was performed for 24 hours at 48 °C in a Binder oven, and staining and scanning of 
the arrays (94PPARG and 138 PPARGC1ASNPs; DNAFit’s custom microchips) was performed 
using GeneTitan instrumentation (Thermo Fisher Scientific, Waltham, MA, US), all following the 
same Affymetrix high throughput Axiom 2.0 protocol. Data analysis was then performed using a 
raw CEL file data input into the Affymetrix Axiom Analysis Suite (Affymetrix, Santa Clara, CA, 
US). 
 
Analysis of mRNA expression ofPPARG 
Expression of PPARG mRNA was measured via reverse transcription and amplification. Reverse 
transcription was performed with Random Hexamer primer, Revert Aid RT, Ribo Lock RNAse 
inhibitor and dNTP mixture on Gene Amp® PCR System 2700, Applied Biosystems, USA. The 
samples were incubated at 42°C for 1 h, followed by heating at 70°C for 10 min. Amplification was 
performed on a7500 FastReal-time PCR system (Applied Biosystems, USA). The values were 
corrected for-actin mRNA expression. 
 
Statistical analysis 
Statistical analysis was conducted using RStudio software. One-way analysis of variance (ANOVA) 
was applied to determine statistical significance among different groups. The paired t-test was used 
to detect the significance of dynamic changes. P < 0.05 was considered statistically significant. 
Bonferroni’s correction for multiple testing was performed by dividing the P value by the number 
of tests where appropriate. 
 
Results  
Effects of intervention program 
The changes in body compositionand biochemical profile induced by the 3-month exercise 
trainingand hypocaloric diet are summarized in Table 1. As expected, the intervention induced 
significant improvements of triglycerides, LDL, and cholesterol levels, as well as BMI, waist 
circumference, hip circumference, total and visceral fat. 
 
Influence of SNPson PPARGmRNA expression 
Of the 94 analysedPPARG SNPs,none were significantly associated with PPARG mRNA 
expression after correction for multiple testing. The most significant SNP,rs6442311A/G,is located 
in PPARG intron.The rs6442311 AG genotype was associated with increased PPARG expression 
(9.01±0.07%; P = 0.022).  
 
Associations between PPARG andPPARGC1ASNPs and adipose tissue mass 
We evaluated relationships between 94 PPARG and 138 PPARGC1A SNPs and baseline values of 
body fat percentage, visceral fat, and markers of lipid metabolism (HDL, LDL, cholesterol). Of the 
tested PPARG SNPs, only one(rs6442311) of the 94 showed a nominally significant(P = 0.016) 
influence on the initial percentage of body adipose tissue. For individuals with the AG genotype of 
rs6442311the mean values of body fatpercentage and visceral fat were29.3% and 5.5% respectively. 
For individuals withthe AA genotype, the results were41.6 %and 10.5 % respectively(Fig. 1). 
Accordingly, the minor allele of rs6442311 had a negative correlation with the accumulation of 
white adipose tissue, especially of visceral fat, and with a higher ratio of total to visceral fat mass 
(5.33 for carriers and 3.96for non-carriers). 
Of the 136 tested PPARGC1A SNPs,only rs6846769showed a nominally significant 
association with baseline percentage of adipose tissue (P= 0.034). More specifically, the minor 
allelewas correlated with a lower body fat percentage; 41.4 % and 28 % for major and minor alleles, 
respectively (Fig.1). Furthermore,the percentage of visceral fat in minor allele carriers was almost 
two-times lower (9.7 % and 5 %), and the ratio of total adipose fat to visceral fat was higher in 
carriers (5.6) than in non-carriers (4.3).  
 
Associations between PPARGC1ASNPs and blood lipoproteins 
None of the 94 tested PPARGSNPs showed a statistically significant association with HDL, LDL, 
cholesterol or triglycerides.One of the 136 tested PPARGC1A SNPs showed a nominally significant 
influence on blood lipoproteins. The minor allele ofrs4458444 (intron variant) was associated with 
increased HDL(P = 0.0081), and total cholesterol (P = 0.036).One of the 136 tested 
PPARGC1ASNPs demonstrated correlation with increased triglyceride blood concentrations. A 
mean triglyceride concentration of 2.38 mM/l was found in carriers of rs2305681 minor 
allele,whereas the mean of carriers of major allelewas 1.6 mM/l.  
 
Associations between PPARG and PPARGC1A SNPs and fat mass loss  
Only one polymorphism (rs17650401 C/T) within the PPARGC1A gene was found to be associated 
with fat loss efficiency after correction for multiple testing, with T allele carriers showing the 
greatest exercise-induced reduction in body fat percentage (2.5-fold; P=0.00013) compared to non-
carriers. As for the 94 analyzedPPARG SNPs, rs9833097 (P=0.00023) and rs12629751 (P=0.0065) 
have shown nominal associations. Genotypes of rs9833097 (AA, AG, GG) have been shown to be 
associated with different values of weight loss (14.60 %, 4.71%, and 2.82%, respectively). Presence 
of the minor allele ofrs12629751was found to correlate witha twofold increase in weight lossafter 
the three-month moderate exercise program: the percentages ofbodyfat loss were 3.02 % and 6.48 




The effectiveness of physical exercise and diet on fat loss varies considerably between 
individuals13. Our genetic association study was designed to test whether multiple variations in the 
PPARG and PPARGC1A genes can modulate changes in body composition and metabolic variables 
following a3 months supervised fitness program and hypocaloric diet in obese Ukrainian women. 
We also tested the hypothesis that polymorphisms within PPARG gene may influence its 
expression. 
PPARG plays an important role in the control of adipose tissue metabolism, adipocyte 
division and differentiation, fat storage and oxidation in beige and brown adipose tissue14. Exercise 
is known to increase PPARG expression and activity within skeletal muscle, thus promoting 
mitochondrial biogenesis and aerobic respiration15. An increased expression of PPARG offers 
protection against elevated blood glucose levels16; as such, the rs6442311 G allele of the PPARG 
gene which has been shown to be associated in our study with increased PPARG mRNA levels may 
decrease the risk of obesity-induced diabetes and cardiovascular diseases. Indeed, we found that 
PPARG rs6442311 G allele was also associated with decreased percentage of the visceral fat at 
baseline. 
Body fat percentage, visceral fat, and markers of lipid metabolism (HDL, LDL, 
cholesterol)are strongly related to the risk of metabolic syndrome, type 2 diabetes, and 
cardiovascular diseases17. BesidesPPARG rs6442311, the rs6846769 polymorphism in the 
PPARGC1A gene showed a nominally significant association with baseline percentage of adipose 
tissue. Thers6846769 SNP may protect against the accumulation of visceral fat in an obese person 
under the influence of environmental factors via the activation of adaptive thermogenesis in brown 
adipose tissue18. This SNP is located inthe first intron of PPARGC1A, prior to the protein coding 
sequence, and may participate in the control of PPARGC1A gene expression. Enhanced 
PPARGC1A expression protects from visceral adipose tissue accumulation, increases total adipose 
to visceral fat ratio, and reduces total body fat content19. Furthermore, the minor allele of the 
PPARGC1A gene rs4458444 polymorphism was associated with increased HDL and total 
cholesterol. Previously20,21 it was shown that decreased expression of PPARGC1A may upregulate 
liver lipoprotein synthesis and downregulate systemic utilization of cholesterol lipoproteins. In 
addition,the PPARGC1A rs2305681 SNP was found to be associated with triglyceride 
concentration. Decreased activity of PPARGC1A is associated with increased blood triglyceride 
levels 7 and risk of cardiovascular disease, especially under the influence of environmental factors 
which induce obesity. Previously, rs2305681 showed strong correlation with anxiety disorders22 via 
possible activation of the antioxidant system within GABA neurons23. Interestingly, PPARGC1A 
rs3774909 (which is in 100% linkage disequilibrium (LD) with rs2305681) has been shown 
previously to be associated with endurance performance24, presumably via regulation of oxidative 
phosphorylation, skeletal muscle mitochondrial biogenesis, and alteration of muscle fiber types.   
We have also shown thatrs17650401 C/T within the PPARGC1A gene was associated with 
fat loss efficiency after correction for multiple testing. This is in line with the studies showing that 
various types of exercises (acute, high intensity interval, and aerobic) induce expression of 
PPARGC1A in the group of overweight people25, which was accompanied with fatty acid 
oxidation26. Moreover, the increased PPARGC1A activity was independent of the glycemic index of 
the diets27 and mostly induced by the exercise program. 
Furthermore, we found two candidate markers within PPARG (rs12629751 and rs9833097) 
that have shown nominal associations. Interestingly, the minor allele of rs12629751,which 
correlated with a twofold increase in weight loss, previously demonstrated a protective property 
against breast cancer28. In addition, the polymorphism within rs7626560 (which is in LD with 
rs9833097) correlated with response to diabetes preventive lifestyle interventions incidence29, 
where participants were advised to perform 150 min per week of physical activity (in our study, 
participants exercised 180 min per week).  
All nominally significant SNPsidentified within this researchare located in the intron region. 
There is no data about the intronic SNPseffects on PPARGC1A or PPARG expression. Hence, these 
SNPs may belong to regulatory post-transcriptional sequences producing miRNA. Also, a changing 
of the nucleotides upstream of promotor region may lead to another nucleosome positioning, thus 
altering promoter strength and its interaction with transcriptional factors. Altogether, we suggest 
this leads to a different expression response to the same environmental factors, such as diet, age and 
physical exercises;this hypothesis is illustrated on Fig 2. 
 
Conclusion 
An intervention comprised of physical activity and a hypocaloric diet has a significant impact on fat 
loss. Individual variability in fat loss efficiency may partly depend on the rs17650401 C/T 
polymorphism within the PPARGC1A gene. The identified SNP,along with many others may be 
helpfulin designingindividual weight loss programsfocused on exercise and/or nutrition. Further 
studies are warranted to test if this variation affects fat oxidation and is associated with fat loss 
efficiency in other ethnicities. 
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Fig. 1. Associations between PPARG rs6442311 and PPARGC1A rs6846769 polymorphisms and 
percentage of total and visceral adipose tissue in obese women (BMI>30 kg/m2). 
 



































Triglycerides, mM/l 1.58±0.78 1.47±1.04 0.756 
LDL, mM/l 3.21±1.16 2.86±0.98 0.016* 
HDL, mM/l 1.44±0.3 1.41±0.28 0.549 
Cholesterol, mM/l 5.32±1.23 4.81±1.08 0.022* 
BMI, kg/m2 33.2±2.9 30.4±3.7 <0.00001* 
Waist circumference, cm 92.4±8.9 85.9±8.9 <0.00001* 
Hip circumference, cm 115.3±7.1 107.9±7.7 <0.00001* 
Total fat, % 40.3±5.3 36.4±5.7 <0.00001* 
Visceral fat, % 9.5±2.4 8.1±2.2 <0.00001* 
 
*P < 0.05, statistically significant differences (paired t-test). 
 
